This page has only limited features, please log in for full access.
A resident in Obstetrics and Gynecology currently working in Gynecologic Oncology Department in Ob&Gyn Hospital of Poznan University of Medical Sciences. She is interested in ovarian cancer research. During her carrier has completed many international internships, e.g. in Spain, Peru and the Netherlands. Since 06.2015 she is an Executive Member ENTOG (European Network of Trainees in Obstetrics and Gynaecology).
Gynecological and breast cancers still remain a significant health problem worldwide. Diagnostic methods are not sensitive and specific enough to detect the disease at an early stage. During carcinogenesis and tumor progression, the cellular need for DNA and protein synthesis increases leading to changes in the levels of amino acids. An important role of amino acids in many biological pathways, including biosynthesis of proteins, nucleic acids, enzymes, etc., which serve as an energy source and maintain redox balance, has been highlighted in many research articles. The aim of this review is a detailed analysis of the literature on metabolomic studies of gynecology and breast cancers with particular emphasis on alterations in free amino acid profiles. The work includes a brief overview of the metabolomic methodology and types of biological samples used in the studies. Special attention was paid to the possible role of selected amino acids in the carcinogenesis, especially proline and amino acids related to its metabolism. There is a clear need for further research and multiple external validation studies to establish the role of amino acid profiling in diagnosing gynecological and breast cancers.
Dagmara Pietkiewicz; Agnieszka Klupczynska-Gabryszak; Szymon Plewa; Magdalena Misiura; Agnieszka Horala; Wojciech Miltyk; Ewa Nowak-Markwitz; Zenon Kokot; Jan Matysiak. Free Amino Acid Alterations in Patients with Gynecological and Breast Cancer: A Review. Pharmaceuticals 2021, 14, 731 .
AMA StyleDagmara Pietkiewicz, Agnieszka Klupczynska-Gabryszak, Szymon Plewa, Magdalena Misiura, Agnieszka Horala, Wojciech Miltyk, Ewa Nowak-Markwitz, Zenon Kokot, Jan Matysiak. Free Amino Acid Alterations in Patients with Gynecological and Breast Cancer: A Review. Pharmaceuticals. 2021; 14 (8):731.
Chicago/Turabian StyleDagmara Pietkiewicz; Agnieszka Klupczynska-Gabryszak; Szymon Plewa; Magdalena Misiura; Agnieszka Horala; Wojciech Miltyk; Ewa Nowak-Markwitz; Zenon Kokot; Jan Matysiak. 2021. "Free Amino Acid Alterations in Patients with Gynecological and Breast Cancer: A Review." Pharmaceuticals 14, no. 8: 731.
Objective The purpose of this study is to evaluate how the obstetrics and gynaecology residency program and trainees have been affected by the Corona Virus Disease-19 (COVID-19) pandemic in Europe. Study Design This study is a cross-sectional explorative survey using an online questionnaire. The questionnaire comprised of 40 questions that were subdivided into 4 subjects; workload, specialist training aspects in obstetrics and gynaecology, health and safety of the trainee and women's health and maternal health issues. Inclusion criteria consisted of being a trainee in Obstetrics and Gynaecology (ObGyn) at the time of the COVID-19 pandemic in Europe or trainees who had recently finished their training during the time of the outbreak. Taking part in the survey was voluntary. The questionnaire was shared on the website of the European Network for Trainees in Obstetrics and Gynaecology (ENTOG), ENTOG social media, in the ENTOG-newsletter and through the national representatives of ENTOG. Results 110 ObGyn trainees from 25 different countries responded to the questionnaire. Almost all trainees (95 %, N=105) reported an effect on their training due to COVID-19 pandemic. Training was interrupted in 21 % of cases (n = 23). Trainees observed a decrease in educational activities or lectures and a decrease in number of patients. The possibility of training surgical skills decreased, because 67 % (N = 74) trainees reported that surgeries were cancelled. Trainees expressed concerns about reaching the goals of their ObGyn specialist training in 60 % (n = 66) of cases. A decrease in workload was experienced during the first COVID-19 wave in Europe by 60 % (n = 66) of trainees. On average these trainees worked 33 % less hours compared to a normal workweek. Although 22 % (n = 24) were expected to be available continuously for 24 h a day and 7 days a week for unscheduled duties, 15 % (n = 16) were deployed to work on special COVID-units. Concerning preparation, 45 % of the trainees (n = 50) had not received any training for treating COVID-positive patients. Trainees claimed to have enough personal protective equipment (PPE), although problems were reported. Any form of psychosocial support was arranged for 65 % of trainees (n = 71) by the hospital or department. The results of the survey suggest that obstetric care was not affected much (92 % (n = 102) of the respondents said at least necessary care continued) while patients in need for reproductive medicine were affected the most; out of the 110 departments 58 % (n = 60) were closed and 35 % (n = 36) reduced their activities. Access to family planning and benign gynaecology were also significantly reduced; 77 % and 87 % respectively of the departments were less accessible or only open to emergency cases. Conclusion COVID-19 pandemic has had a tremendous effect on the ObGyn training in Europe. Exposure to learning opportunities, surgeries and teaching has been decreased during the outbreak and may result in a decrease in quality of care provided to women in the future if impairment of training is not recovered.
Ferry Boekhorst; Hajra Khattak; Elif Goknur Topcu; Agnieszka Horala; Manuel Gonçalves Henriques. The influence of the COVID-19 outbreak on European trainees in obstetrics and gynaecology: A survey of the impact on training and trainee. European Journal of Obstetrics & Gynecology and Reproductive Biology 2021, 261, 52 -58.
AMA StyleFerry Boekhorst, Hajra Khattak, Elif Goknur Topcu, Agnieszka Horala, Manuel Gonçalves Henriques. The influence of the COVID-19 outbreak on European trainees in obstetrics and gynaecology: A survey of the impact on training and trainee. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021; 261 ():52-58.
Chicago/Turabian StyleFerry Boekhorst; Hajra Khattak; Elif Goknur Topcu; Agnieszka Horala; Manuel Gonçalves Henriques. 2021. "The influence of the COVID-19 outbreak on European trainees in obstetrics and gynaecology: A survey of the impact on training and trainee." European Journal of Obstetrics & Gynecology and Reproductive Biology 261, no. : 52-58.
Proper preoperative ovarian cancer (OC) diagnosis remains challenging. Serum free amino acid (SFAA) profiles were investigated to identify potential novel biomarkers of OC and assess their performance in ovarian tumor differential diagnosis. Serum samples were divided based on the histopathological result: epithelial OC (n = 38), borderline ovarian tumors (n = 6), and benign ovarian tumors (BOTs) (n = 62). SFAA profiles were evaluated using aTRAQ methodology based on high-performance liquid chromatography electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). Levels of eleven amino acids significantly differed between OC+borderline and BOTs. The highest area under the receiver operating characteristic curve (AUC of ROC) (0.787) was obtained for histidine. Cystine and histidine were identified as best single markers for early stage OC/BOT and type I OC. For advanced stage OC, seven amino acids differed significantly between the groups and citrulline obtained the best AUC of 0.807. Between type II OC and BOTs, eight amino acids differed significantly and the highest AUC of 0.798 was achieved by histidine and citrulline (AUC of 0.778). Histidine was identified as a potential new biomarker in differential diagnosis of ovarian tumors. Adding histidine to a multimarker panel together with CA125 and HE4 improved the differential diagnosis between OC and BOTs.
Agnieszka Horala; Szymon Plewa; Pawel Derezinski; Agnieszka Klupczynska; Jan Matysiak; Ewa Nowak-Markwitz; Zenon Kokot. Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors—A Comparative Study with Review of the Literature. International Journal of Environmental Research and Public Health 2021, 18, 2167 .
AMA StyleAgnieszka Horala, Szymon Plewa, Pawel Derezinski, Agnieszka Klupczynska, Jan Matysiak, Ewa Nowak-Markwitz, Zenon Kokot. Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors—A Comparative Study with Review of the Literature. International Journal of Environmental Research and Public Health. 2021; 18 (4):2167.
Chicago/Turabian StyleAgnieszka Horala; Szymon Plewa; Pawel Derezinski; Agnieszka Klupczynska; Jan Matysiak; Ewa Nowak-Markwitz; Zenon Kokot. 2021. "Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors—A Comparative Study with Review of the Literature." International Journal of Environmental Research and Public Health 18, no. 4: 2167.
Background Due to lack of effective early diagnostic methods, ovarian cancer (OC) remains a disease with a very unfavorable prognosis and correct differentiation between benign and malignant ovarian tumors is often difficult. Metabolomic profiling has recently been widely used in the search for non-invasive cancer diagnostic methods. In this research the serum free amino acid profiles were investigated to identify potential novel biomarkers of OC and assess their performance in ovarian tumor differential diagnosis. Results Serum samples from patients diagnosed with ovarian tumors were divided based on the histopathological result: epithelial OC (n=38), borderline ovarian tumors (n=6) and benign ovarian tumors (BOTs) (n=62). Serum free amino acid profiles were evaluated using aTRAQ methodology based on high-performance liquid chromatography electrospray ionization tandem mass spectrometry. In the performed analyses, the levels of eleven amino acids significantly differed between OC + borderline and BOTs. The highest AUC (0.787) was obtained for histidine. Cystine and histidine were identified as best single markers for early stage OC/BOT and type I OC. For advanced stage OC, seven amino acids differed significantly between the groups and citrulline obtained the best AUC of 0.807. Between type II OC and BOTs eight amino acids differed significantly and the highest AUC of 0.798 was achieved by histidine and citrulline (AUC of 0.778). Conclusions Serum free amino acid profiles are significantly altered in OC patients as compared to those with BOTs. Histidine emerges as a potential new biomarker in differential diagnosis of ovarian tumors. Adding histidine to a multimarker panel together with CA125 and HE4 improved the differential diagnosis between OC and BOTs.
Agnieszka Horala; Szymon Plewa; Pawel Derezinski; Agnieszak Klupczynska; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J Kokot. Serum free amino acid profiling in differential diagnosis of ovarian tumors – a case control study with review of the literature. 2020, 1 .
AMA StyleAgnieszka Horala, Szymon Plewa, Pawel Derezinski, Agnieszak Klupczynska, Jan Matysiak, Ewa Nowak-Markwitz, Zenon J Kokot. Serum free amino acid profiling in differential diagnosis of ovarian tumors – a case control study with review of the literature. . 2020; ():1.
Chicago/Turabian StyleAgnieszka Horala; Szymon Plewa; Pawel Derezinski; Agnieszak Klupczynska; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J Kokot. 2020. "Serum free amino acid profiling in differential diagnosis of ovarian tumors – a case control study with review of the literature." , no. : 1.
This study presents the use of matrix-assisted laser desorption and ionization mass spectrometry imaging (MALDI-MSI) directly on the tissue of two ovarian tumors that often present a diagnostic challenge, a low-grade serous borderline ovarian tumor and ovarian fibrothecoma. Different spatial distribution of m/z values within the tissue samples was observed, and regiospecific peaks were identified. Among the 106 peaks in the borderline ovarian tumor five, regiospecific peaks (m/z: 2861.35; 2775.79; 3368.34; 3438.43; 4936.37) were selected using FlexImaging software. Subsequently, the distribution of those selected peaks was visualized on the fibrothecoma tissue section, which demonstrated the differences in the tissue homo-/heterogeneous structure of both tumors. The comparison with the histopathological staining of the ovarian borderline tumor tissue section, obtained during serial sectioning, showed a close correlation of the molecular map with the morphological and histopathological features of the tissue and allowed the identification of different tissue types within the sample. This study highlights the potential significance of MSI in enabling morphological characterization of ovarian tumors as well as correct diagnosis and further prognosis than thus far seen in the literature. Osteopontin, tropomyosin and orosomucoid are only a couple of the molecules investigated using MALDI-MSI in ovarian cancer research. This study, in line with the available literature, proves the potential of MALDI-MSI to overcome the current limitations of classic histopathological examination giving a more in-depth insight into the tissue structure and thus lead to the more accurate differential diagnosis of ovarian tumors, especially in the most challenging cases.
Dagmara Pietkiewicz; Agnieszka Horała; Szymon Plewa; Piotr Jasiński; Ewa Nowak-Markwitz; Zenon J. Kokot; Jan Matysiak. MALDI-MSI—A Step Forward in Overcoming the Diagnostic Challenges in Ovarian Tumors. International Journal of Environmental Research and Public Health 2020, 17, 7564 .
AMA StyleDagmara Pietkiewicz, Agnieszka Horała, Szymon Plewa, Piotr Jasiński, Ewa Nowak-Markwitz, Zenon J. Kokot, Jan Matysiak. MALDI-MSI—A Step Forward in Overcoming the Diagnostic Challenges in Ovarian Tumors. International Journal of Environmental Research and Public Health. 2020; 17 (20):7564.
Chicago/Turabian StyleDagmara Pietkiewicz; Agnieszka Horała; Szymon Plewa; Piotr Jasiński; Ewa Nowak-Markwitz; Zenon J. Kokot; Jan Matysiak. 2020. "MALDI-MSI—A Step Forward in Overcoming the Diagnostic Challenges in Ovarian Tumors." International Journal of Environmental Research and Public Health 17, no. 20: 7564.
Ovarian cancer (OC) diagnosis remains a clinical challenge due to lack of early symptoms and insufficient accuracy of the available diagnostic methods. The purpose of this study was to determine whether osteopontin could be useful in differential diagnosis of ovarian tumors. Serum samples from 92 patients qualified for surgical treatment due to ovarian mass were divided into 2 groups according to the histopathological result: OC including borderline ovarian tumors (n = 39) and benign ovarian tumors (BOTs) (n = 53). CA125, HE4 and osteopontin concentrations were measured in all patients. Areas under the receiver operating characteristic curves (AUC of ROC) were used to compare the discriminative ability of the univariate and multivariate diagnostic models. The addition of osteopontin to ROMA significantly improved the diagnostic performance of the test in 3 of the 5 analyses: 1) in the OC vs BOT group (from AUC of 0.955 to 0.975), 2) in premenopausal women OC vs BOT (from AUC of 0.828 to 0.892) and 3) in the FIGO I-II stage OC vs BOT (from AUC of 0.865 to 0.895). It did not alter the diagnostic performance of multifactor tests in the group of postmenopausal women nor in OC FIGO III-IV stage group. Osteopontin was also the best single marker to differentiate between early stage OC and BOTs (AUC of 0.863). Osteopontin improves the diagnostic performance of a multimarker OC diagnostic test and could be useful in differential diagnosis of ovarian tumors, especially in pre-menopausal women and for early stage OC.
Agnieszka Horała; Agata Swiatly; Jakub Lorek; Zenon J Kokot; Jan Matysiak; Ewa Nowak-Markwitz. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors. Ginekologia Polska 2018, 89, 568 -572.
AMA StyleAgnieszka Horała, Agata Swiatly, Jakub Lorek, Zenon J Kokot, Jan Matysiak, Ewa Nowak-Markwitz. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors. Ginekologia Polska. 2018; 89 (10):568-572.
Chicago/Turabian StyleAgnieszka Horała; Agata Swiatly; Jakub Lorek; Zenon J Kokot; Jan Matysiak; Ewa Nowak-Markwitz. 2018. "Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors." Ginekologia Polska 89, no. 10: 568-572.
Despite many years of studies, ovarian cancer remains one of the top ten cancers worldwide. Its high mortality rate is mainly due to lack of sufficient diagnostic methods. For this reason, our research focused on the identification of blood markers whose appearance would precede the clinical manifestation of the disease. ITRAQ-tagging (isobaric Tags for Relative and Absolute Quantification) coupled with mass spectrometry technology was applied. Three groups of samples derived from patients with: ovarian cancer, benign ovarian tumor, and healthy controls, were examined. Mass spectrometry analysis allowed for highlighting the dysregulation of several proteins associated with ovarian cancer. Further validation of the obtained results indicated that five proteins (Serotransferrin, Amyloid A1, Hemopexin, C-reactive protein, Albumin) were differentially expressed in ovarian cancer group. Interestingly, the addition of Albumin, Serotransferrin, and Amyloid A1 to CA125 (cancer antigen 125) and HE4 (human epididymis protein4) improved the diagnostic performance of the model discriminating between benign and malignant tumors. Identified proteins shed light on the molecular signaling pathways that are associated with ovarian cancer development and should be further investigated in future studies. Our findings indicate five proteins with a strong potential to use in a multimarker test for screening and detection of ovarian cancer.
Agata Swiatly; Agnieszka Horala; Jan Matysiak; Joanna Hajduk; Ewa Nowak-Markwitz; Zenon J. Kokot. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery. International Journal of Molecular Sciences 2018, 19, 2240 .
AMA StyleAgata Swiatly, Agnieszka Horala, Jan Matysiak, Joanna Hajduk, Ewa Nowak-Markwitz, Zenon J. Kokot. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery. International Journal of Molecular Sciences. 2018; 19 (8):2240.
Chicago/Turabian StyleAgata Swiatly; Agnieszka Horala; Jan Matysiak; Joanna Hajduk; Ewa Nowak-Markwitz; Zenon J. Kokot. 2018. "Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery." International Journal of Molecular Sciences 19, no. 8: 2240.
The aim of this study was to quantitate 42 serum-free amino acids, propose the biochemical explanation of their role in tumor development, and identify new ovarian cancer (OC) biomarkers for potential use in OC screening. The additional value of this work is the schematic presentation of the interrelationship between metabolites which were identified as significant for OC development and progression. The liquid chromatography-tandem mass spectrometry technique using highly-selective multiple reaction monitoring mode and labeled internal standards for each analyzed compound was applied. Performed statistical analyses showed that amino acids are potentially useful as OC biomarkers, especially as variables in multi-marker models. For the distinguishing metabolites the following metabolic pathways involved in cancer growth and development were proposed: histidine metabolism; tryptophan metabolism; arginine biosynthesis; arginine and proline metabolism; and alanine, aspartate and glutamine metabolism. The presented research identifies histidine and citrulline as potential new OC biomarkers. Furthermore, it provides evidence that amino acids are involved in metabolic pathways related to tumor growth and play an important role in cancerogenesis.
Szymon Plewa; Agnieszka Horała; Paweł Dereziński; Agnieszka Klupczynska; Ewa Nowak-Markwitz; Jan Matysiak; Zenon J. Kokot. Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis. International Journal of Molecular Sciences 2017, 18, 2727 .
AMA StyleSzymon Plewa, Agnieszka Horała, Paweł Dereziński, Agnieszka Klupczynska, Ewa Nowak-Markwitz, Jan Matysiak, Zenon J. Kokot. Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis. International Journal of Molecular Sciences. 2017; 18 (12):2727.
Chicago/Turabian StyleSzymon Plewa; Agnieszka Horała; Paweł Dereziński; Agnieszka Klupczynska; Ewa Nowak-Markwitz; Jan Matysiak; Zenon J. Kokot. 2017. "Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis." International Journal of Molecular Sciences 18, no. 12: 2727.
Due to high mortality and lack of efficient screening, new tools for ovarian cancer (OC) diagnosis are urgently needed. To broaden the knowledge on the pathological processes that occur during ovarian cancer tumorigenesis, protein-peptide profiling was proposed. Serum proteomic patterns in samples from OC patients were obtained using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). Eighty nine serum samples (44 ovarian cancer and 45 healthy controls) were pretreated using solid-phase extraction method. Next, a classification model with the most discriminative factors was identified using chemometric algorithms. Finally, the results were verified by external validation on an independent test set of samples. Main outcome of this study was an identification of potential OC biomarkers by applying liquid chromatography coupled with tandem mass spectrometry. Application of this novel strategy enabled the identification of four potential OC serum biomarkers (complement C3, kininogen-1, inter-alpha-trypsin inhibitor heavy chain H4, and transthyretin). The role of these proteins was discussed in relation to OC pathomechanism. The study results may contribute to the development of clinically useful multi-component diagnostic tools in OC. In addition, identifying a novel panel of discriminative proteins could provide a new insight into complex signaling and functional networks associated with this multifactorial disease.
Agata Swiatly; Agnieszka Horala; Joanna Hajduk; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J. Kokot. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer. BMC Cancer 2017, 17, 1 -9.
AMA StyleAgata Swiatly, Agnieszka Horala, Joanna Hajduk, Jan Matysiak, Ewa Nowak-Markwitz, Zenon J. Kokot. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer. BMC Cancer. 2017; 17 (1):1-9.
Chicago/Turabian StyleAgata Swiatly; Agnieszka Horala; Joanna Hajduk; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J. Kokot. 2017. "MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer." BMC Cancer 17, no. 1: 1-9.
As cancer development involves pathological vessel formation, 16 angiogenesis markers were evaluated as potential ovarian cancer (OC) biomarkers. Blood samples collected from 172 patients were divided based on histopathological result: OC (n = 38), borderline ovarian tumours (n = 6), non-malignant ovarian tumours (n = 62), healthy controls (n = 50) and 16 patients were excluded. Sixteen angiogenesis markers were measured using BioPlex Pro Human Cancer Biomarker Panel 1 immunoassay. Additionally, concentrations of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) were measured in patients with adnexal masses using electrochemiluminescence immunoassay. In the comparison between OC vs. non-OC, osteopontin achieved the highest area under the curve (AUC) of 0.79 (sensitivity 69%, specificity 78%). Multimarker models based on four to six markers (basic fibroblast growth factor—FGF-basic, follistatin, hepatocyte growth factor—HGF, osteopontin, platelet-derived growth factor AB/BB—PDGF-AB/BB, leptin) demonstrated higher discriminatory ability (AUC 0.80–0.81) than a single marker (AUC 0.79). When comparing OC with benign ovarian tumours, six markers had statistically different expression (osteopontin, leptin, follistatin, PDGF-AB/BB, HGF, FGF-basic). Osteopontin was the best single angiogenesis marker (AUC 0.825, sensitivity 72%, specificity 82%). A three-marker panel consisting of osteopontin, CA125 and HE4 better discriminated the groups (AUC 0.958) than HE4 or CA125 alone (AUC 0.941 and 0.932, respectively). Osteopontin should be further investigated as a potential biomarker in OC screening and differential diagnosis of ovarian tumours. Adding osteopontin to a panel of already used biomarkers (CA125 and HE4) significantly improves differential diagnosis between malignant and benign ovarian tumours.
Agnieszka Horala; Agata Swiatly; Jan Matysiak; Paulina Banach; Ewa Nowak-Markwitz; Zenon J. Kokot. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay. International Journal of Molecular Sciences 2017, 18, 123 .
AMA StyleAgnieszka Horala, Agata Swiatly, Jan Matysiak, Paulina Banach, Ewa Nowak-Markwitz, Zenon J. Kokot. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay. International Journal of Molecular Sciences. 2017; 18 (1):123.
Chicago/Turabian StyleAgnieszka Horala; Agata Swiatly; Jan Matysiak; Paulina Banach; Ewa Nowak-Markwitz; Zenon J. Kokot. 2017. "Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay." International Journal of Molecular Sciences 18, no. 1: 123.
The project entitled ”Proteomic and metabolomic strategy of searching for biomarkers of genital cancer diseases using mass spectrometry methods” is a study based on novel omics techniques. The main assumption of this research is the development of innovative model of searching of biomarkers in ovarian and prostate cancers using proteomics and metabolomics methodologies supported by bioinformatics analysis. The innovatory strategy based on the latest achievements in the field of mass spectrometry will allow for the implementation of the unique studies for discovery new biomarkers, which are useful in prediction, diagnosis and treatment of the genital cancers. To date, there is no comprehensive data including set of proteins and other endogenous compounds involved in the development and differentiation of these diseases. Therefore, the proposed approach may contribute to the discovery of biomarkers with high sensitivity and specificity, which will provide new information about genital cancers characterization.
Jan Matysiak; Paweł Dereziński; Agnieszka Klupczyńska; Joanna Hajduk; Agata Światły; Szymon Plewa; Agnieszka Horała; Patryk Jaźwiński; Paulina Banach; Ewa Nowak-Markwitz; Zenon J. Kokot. Proteomic and metabolomic strategy of searching for biomarkers of genital cancer diseases using mass spectrometry methods. Journal of Medical Science 2016, 85, 330 .
AMA StyleJan Matysiak, Paweł Dereziński, Agnieszka Klupczyńska, Joanna Hajduk, Agata Światły, Szymon Plewa, Agnieszka Horała, Patryk Jaźwiński, Paulina Banach, Ewa Nowak-Markwitz, Zenon J. Kokot. Proteomic and metabolomic strategy of searching for biomarkers of genital cancer diseases using mass spectrometry methods. Journal of Medical Science. 2016; 85 (4):330.
Chicago/Turabian StyleJan Matysiak; Paweł Dereziński; Agnieszka Klupczyńska; Joanna Hajduk; Agata Światły; Szymon Plewa; Agnieszka Horała; Patryk Jaźwiński; Paulina Banach; Ewa Nowak-Markwitz; Zenon J. Kokot. 2016. "Proteomic and metabolomic strategy of searching for biomarkers of genital cancer diseases using mass spectrometry methods." Journal of Medical Science 85, no. 4: 330.
Since metformin was reported to decrease overall cancer incidence and mortality and to have antiproliferative and antinvasive properties, we investigated the impact of metformin intake on survival in endometrial cancer patients. Medical records and survival data of 126 patients with endometrial cancer were analyzed retrospectively U Mann-Whitney and chi-square tests were applied to compare clinicopathological features. Kaplan Meier model with log-rank test was used to compare survival in the subgroups. Cox proportional hazard model was applied to analyze the relationships between particular factors and overall survival. 107 patients met study criteria and were divided into three groups: 1) patients with type 2 diabetes and metformin users (n = 30), 2) patients with type 2 diabetes and metformin non-users (n = 38), 3) patients without diabetes mellitus (n = 39). No difference in survival between metformin users versus metformin non-users (p = 0.86) was observed. Metformin intake, diabetes mellitus co morbidity, plasma glucose level and BMI appeared without influence on survival. When the analysis was restricted to the subgroup of type I endometrial cancer or to endometroid histological type, still neither metformin intake nor diabetes influenced the prognosis. Metformin intake does not alter overall survival in endometrial cancer patients. Diabetes mellitus has no influence on survival in endometrial cancer patients.
Agnieszka Lemańska; Mikołaj Zaborowski; Marek Spaczyński; Ewa Nowak-Markwitz. Do endometrial cancer patients benefit from metformin intake? Ginekologia Polska 2015, 86, 419 -423.
AMA StyleAgnieszka Lemańska, Mikołaj Zaborowski, Marek Spaczyński, Ewa Nowak-Markwitz. Do endometrial cancer patients benefit from metformin intake? Ginekologia Polska. 2015; 86 (6):419-423.
Chicago/Turabian StyleAgnieszka Lemańska; Mikołaj Zaborowski; Marek Spaczyński; Ewa Nowak-Markwitz. 2015. "Do endometrial cancer patients benefit from metformin intake?" Ginekologia Polska 86, no. 6: 419-423.